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ABSTRACT
Rapid spread of severe acute respiratory syndrome coranovirus-2 virus (SARS-CoV-2) caused the pandemic of Coronavirus 
Disease 19 (COVID-19). Clinical course of the disease presents symptoms mainly from the respiratory system such as: cough, 
dyspnea and fever, and among some patients, can deteriorate even further to acute respiratory distress syndrome (ARDS), 
eventually leading to death. This outbreak, as well as previous ones (SARS, MERS) pose a significant challenge for health 
care managers, epidemiologists and physicians. Below we are presenting the clinical profile of the COVID-19 among special 
group of patients; pregnant women and newborns, who require special clinical management during hospitalization. In the 
summary of this manuscript, we present practical guidelines for managing pregnant women infected with SARS-CoV-2, 
labor and care of the newborn of a positive mother, as well as practical guidelines for COVID-19 vaccinations. It is important 
to stress, that this manuscript is based on information available as of December 2020.  
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INTRODUCTION
SARS-CoV-2 belongs to a group of spherical enveloped 
RNA viruses, the beta subtype of coronaviruses. As of 2019, 
six viruses of this group were known to cause infections in 
humans. Four of them (229E, OC43, NL63, HKU1) are known 
to cause a mild infection in people. The remaining two have 
shown to be the cause life-threatening acute respiratory dis-
tress syndrome (ARDS): SARS (severe acute respiratory syn-
drome) caused by SARS-CoV and MERS (Middle East respirato-
ry syndrome) caused by MERS-CoV [1–3]. COVID-19 is a disease 
caused by the Wuhan coronavirus (SARS-CoV-2). The name 
COVID-19 developed by the World Health Organization (WHO) 
stands for “CO” — corona, “VI” — virus, “D” — disease, and the 
number 19 indicates the year the virus appeared — 2019 (Co-
rona-Virus-Disease-2019) [3]. By December 31, 2020, there 
were 85 899 563 confirmed cases and 1 858 412 deaths due 
to COVID-19. The rapid spread of the virus along with a severe 
clinical course of disease in most hospitalized patients raises 
questions about the risks of COVID-19 on people with an in-
creased risk of infection. Based on this information, it is neces-
sary to establish special procedures that will be used for the 
prevention, diagnosis and treatment of COVID-19, especially 
for pregnant women during labor and newborns who present 
to the hospital with symptoms of infection. 
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CLINICAL MANIfESTATION Of COVID-19 
INfECTION IN PREGNANCy
The results based on 28 studies and 11,432 patients 
selected for the systematic review found that from 7–14% 
of pregnant women presenting or admitted to the hospital 
tested positive for COVID-19; 85% of them had infection 
identified in third trimester. Of these positive women 75% 
were asymptomatic, severe COVID-19 was diagnosed in 
13% of pregnant women, 4% was admitted to Intensive 
Care Unit (ICU) and 3% required invasive mechanical venti-
lation. Pregnant women with COVID-19 manifested fewer 
symptoms than general population while the predominant 
features of symptomatic COVID-19 in pregnant women were 
cough (33%) and fever (29%). Compared to non-pregnant 
women with COVID-19 pregnant women were less likely to 
report fever (OR = 0.48 CI: 0.22–0.85) and myalgia (OR = 0.48 
CI: 0.45–0.51) [1, 2].
Among pregnant women with COVID-19 infection 
leukopenia (66.1%) and lymphopenia (48.3%) were the 
most common laboratory abnormality (66.1%) with other 
common abnormalities like elevated: CRP, D-dimer, lactate 
dehydrogenase (LDH) and IL-6. Combination of elevated 
D-dimer and IL-6 was associated with more severe disease 
and found in 60% of severely ill and in 80% of critically ill 
pregnant women, respectively. 
Unilateral or bilateral ground-glass opacities were the 
most common imaging findings. Observed mortality rates 
for pregnant women with COVID-19 were 0.1-2.0% what is 
comparable to general population, but pregnant women 
were more likely to require mechanical ventilation and ad-
mission to an ICU; (OR = 1.62 CI: 1.33–1.96) [1].  As much 
as 40% of pregnant women who died from COVID-19 had 
obesity, diabetes or maternal age over 40 years. 
CORONAVIRUSES AND THE OCCURRENCE Of 
fETAL MALfORMATIONS
There is currently insufficient evidence that coronavirus 
infection has a negative impact on the incidence of fetal 
defects. This applies to the “common cold” coronaviruses 
as well as SARS, MERS and SARS-CoV-2. The frequency of 
malformations in the offspring of infected women does not 
differ from the population average. This is possibly related to 
the low risk of vertical viral transmission due to short period 
of viremia and poor ACE-2 expression in the placenta. In the 
case of SARS-CoV-2, the estimated frequency of infection 
by this route may be 2.6% according to the CDC report. 
However, the negative impact of fever, one of the most 
common symptoms of COVID-19, on the occurrence of 
fetal malformations should not be underestimated. Among 
single congenital defects, the most common were heart 
defects, cleft lip palate, defects of the genitourinary system 
and chromosomal disorders. The use of anti-fever medica-
tions in the first trimester of pregnancy is very important. 
Paracetamol should be used as the first-line drug, while 
avoiding non-steroidal anti-inflammatory drugs, the use of 
which during this period increases the risk of such defects as 
gastroschisis, hypophysis, anencephaly, cleft lip/palate and 
spina bifida [3–5]. However, it should be noted that there 
are still too few reported cases of confirmed COVID-19 in 
early pregnancy, which makes it impossible to draw final 
conclusions supported by evidence-based medicine criteria.
THE IMPACT Of COVID-19 INfECTION ON 
PREGNANCy OUTCOMES
Knowledge regarding impact of COVID-19 on perinatal 
outcomes is limited due to small study population, different 
testing methods ranging from universal SARS-CoV-2 testing 
for all pregnant women to symptom-based testing, high 
heterogeneity of study population and lack of long-term 
follow-up. Some studies showed higher incidence of pre-
term birth in COVID-19 positive patients, but the rate of 
preterm birth was increased in COVID-19 mothers regardless 
of the severity of the disease. It is important to stress that 
caesarean sections account for nearly all preterm deliveries, 
which suggests the iatrogenic origin of preterm delivery. 
The PRIORITY study found no increased risk of preterm 
birth in COVID positive mothers with exception to moth-
ers who tested positive 0-14 day before delivery. Similarly, 
meta-analysis published by Allotey et al. [1], indicated that 
overall rate of spontaneous preterm birth was not elevated 
–and reached only six percent. Overall, it seems that sponta-
neous preterm labour is not increased compared to general 
population.  There are some data, although limited, indicat-
ing that miscarriage and stillbirth rates are not increased 
in COVID-19 positive pregnant women [1].  A retrospective 
study showed that miscarriage rate in pandemic period did 
not differ to that observed in pre-pandemic period (14.2% 
vs 12.8%; p = 0.76). Further data of maternal exposure in-
cluding the preconception period is needed to determine 
the effects of COVID-19 on early pregnancy outcomes. 
McDonnell et al. [6], found that in a tertiary referral cent-
er in Dublin, there was no correlation between monthly 
number of COVID-19 deaths in general population and 
the number of perinatal deaths, preterm births, GDM or 
pregnancy induced hypertension including pre-eclampsia. 
There are mixed data indicating COVID-19 impact on the 
SGA rate from 5.7% in meta-analysis from USA to even 17.4% 
reported in Chinese population. Women diagnosed with 
COVID-19 did not have a significantly higher quantitative 
blood loss during delivery and did not present increased 
risk of obstetric hemorrhage as compared to those without 
confirmation of COVID-19. Pregnant patients after kidney 
transplant and under immunosuppression complicated 
by COVID-19 infection had higher rates of ICU admission 
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(30–57%) and higher mortality rates of 10–28% and should 
be treated as a high-risk group.  
The results of cross-sectional survey conducted among 
pregnant women in antenatal clinics in Singapore based on 
validated Depression, Anxiety, and Stress Scales (DASS-21) 
showed that 35.8% of women screened positive for anxiety, 
18.2% for depression and 11.1% for stress [7].  It seems that 
lack of timely and reliable information on the impact of 
COVID-19 on pregnancy and its outcome led to increased 
levels of depression, anxiety and stress. Evidenced-based 
information and psychological support should be provided 
for pregnant women by the healthcare providers.  
THE MODE Of DELIVERy IN A PREGNANT 
WOMAN INfECTED WITH SARS COV-2
Rates of SARS-CoV-2 infection in neonates seem to be 
not affected by mode of delivery, feeding nor by direct 
contact with a mother suspected or being positive for 
SARS-CoV-2 infection [8]. The decision on caesarean delivery 
should be based on obstetric (fetal or maternal) indications 
or respiratory status instead of COVID-19 status alone. There 
is no evidence to favour one mode of birth over another 
in women with COVID-19. The final decision regarding the 
mode of delivery should be based on woman’s preferences 
and any obstetric or fetal indications for the intervention 
[9]. In one systematic review, which included 666 neonates 
and 655 women, 28/666 (4%) neonates had confirmed COV-
ID‐19 infection postnatally. Infants born vaginally did not 
have higher risk for COVID infection; 8/292 (2.7%) compared 
with 20/374 (5.3%) born by Caesarean [10]. Gale et al. [11], 
in another publication included 82 infants of 116 positive 
mothers ,from which44% were delivered by Caesarean sec-
tion and 56% vaginally, and none of the infants were posi-
tive for SARS-CoV-2 postnatally in follow-up at 14 of life 
days. The authors concluded that the decision on birth 
mode should be based on medical indications, the course of 
the COVID-19 infection as well as provision of safe working 
conditions for medical staff. In cases of pregnant women 
being positive for COVID-19, there are many issues to be 
considered, however, each medical case should be worked 
out individually.
ANTIVIRAL TREATMENT IN PREGNANT 
WOMEN WITH COVID-19
The vast majority of pregnant women with COVID-19 is 
only mildly symptomatic, however, cases of severe disease 
with pneumonia and respiratory failure have also been 
observed [12]. 
In general, the choice of treatment for COVID-19 in 
pregnancy should be based on the stage of the disease 
and recommendations for the general population. The 
course of COVID-19 can be divided into three clinical stages: 
viremic phase (day 1–7), pulmonary phase (day 5–10) and 
hyperimmune phase (after day 8) [13]. In patients with mild 
symptoms in the viremic phase (with normal oxygen satura-
tion level, that is > 94%), only antipyretic drugs and home 
isolation are recommended. Hospitalization is required in 
all patients with oxygen saturation below 94%. In case of 
COVID-19 symptoms exacerbation, an intravenous of rem-
desivir should be administered for five days, but the treat-
ment is effective if it is started within the first seven days 
from the onset of symptoms [13]. It is not contraindicated in 
pregnant women if the benefits of treatment outweight the 
possible risk of side effects. The drug is generally well toler-
ated, although its effect on the fetus remains unknown [14]. 
If the hyperimmunization phase begins (pneumonia 
with saturation drop < 94%), which occurs mostly after seven 
days of treatment, the use of tocilizumab, an anti-IL-6 mono-
clonal antibody, should be considered. In patients requiring 
hospitalisation, glucocorticosteroids (dexamethasone given 
in a dose of at least 6 mg/day), low-molecular-weight hepa-
rin in a prophylactic dose (prophylaxis of pulmonary em-
bolism) and antibiotics (prophylaxis of superinfection with 
bacterial pneumonia) should be used simultaneously [13]. 
ORGANIzATION Of THE MATERNITy WARD IN 
PANDEMIC PERIOD Of COVID-19
The standard of the organization of the maternity ward 
was included in the regulation of the Polish Minister of 
Health of June 26, 2012 on detailed requirements to be 
met by the premises and equipment of the entity perform-
ing medical activities. The ordinance does not contain in-
formation about isolation rooms, strict supervision rooms 
and rooms with direct access to oxygen within the ma-
ternity ward. The Obstetrics ward is a highly specialized 
hospital unit with a very diverse medical staff (obstetri-
cians, neonatologists, anaesthesiologists, midwives, nurses, 
instrumentalists). The reorganization of maternity wards 
is extremely important in the prevention and control of 
the COVID-19 pandemic not only among patients but also 
among staff. To effectively minimize nosocomial infections 
during the COVID- 19 pandemic period, preventive strategy 
should be applied including ward redesign and partition 
management.  
1. Creation of the three zones fulfilling the need for triage: 
green, yellow and red. Patient with suspected COVID 
infection is managed in the yellow zone, whereas con-
firmed COVID cases are moved to zone red. In selected 
zones, there should be a carefully designated number 
of people who can stay at the same time with suspect-
ed/infected patient. Working time in a protective suit 
is limited up to four hours only. There is strict personal 
protective equipment defined: a barrier suit is obligatory 
protective gear for all medical workers in the red zone.
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2. Patients stay in single or double rooms depending on 
their clinical condition. Medical visits take place twice 
a day and strict nursing supervision is of great impor-
tance, as patients with a severe course of COVID in the 
third trimester of pregnancy can worsen within a few 
hours. 
3. There should be dedicated a separate operating room 
organized exclusively for caesarean sections of patients 
with COVID infection. 
4. The most risky procedure for viral contamination is re-
moving personal protective equipment after medical 
procedures on contagious patients, thus special training 
for this activity needs to be provided. 
5. Appropriate protocols should be prepared regarding 
the order of entry, putting in and removing protective 
gear, moving patients, passing newborns after birth and 
providing postpartum care. 
6. One-way traffic from entering the COVID zone to the 
exit should be implemented. 
The only diagnostic test that guarantees highest quality 
of the presence of the SARS-CoV-2 is RT PCR test. However, 
due to the long waiting time for the result, new generation 
antigen test can be used instead. 
Currently, every hospital with a maternity ward should 
be prepared to admit and temporarily hospitalize a patient 
with COVID infection. That is why it is so important to look 
for individual solutions suitable for a given place.
MASKS AND fAMILy ASSISTED BIRTHS
According to the orders of the Polish government and 
Ministry of Health, everybody should wear masks in public 
spaces and observe the rules of keeping an appropriate 
distance. The hospital should also be recognized as a form 
of public space. The principle of wearing masks applies 
to the staff, patients and those accompanying childbirth. 
Both sides can be a mutual source of infection. This applies 
to all departments, sick rooms, corridors and on-call duty 
rooms for both doctors and midwives. For obvious reasons, 
women in the active phase of labor should be exempt from 
the obligation to wear a mask.
Best protection is provided by type FFP2 or FFP3 masks. 
However, it is worth paying attention to the structure of the 
mask itself. If it has a forward-facing exhaust valve, although 
it protects the mask wearer, it poses a risk to everyone else. 
This type of mask should not be used at all and an additional 
surgical mask should be worn if it is on top. 
fAMILy ASSISTED BIRTHS 
In times of a pandemic, the presence of a loved one in 
childbirth is of great importance for a woman. However, for 
the safety of other patients and staff, the following rules 
must be followed:
a) completing the epidemiological questionnaire by the 
accompanying person during the delivery;
b) the accompanying person must wear a mask and gloves 
throughout the stay in the hospital;
c) the woman in labor and an accompanying person stay in 
a single, individual delivery room equipped with a sepa-
rate sanitary facility;
d) the person accompanying the birthing child may be 
admitted at the beginning of the delivery and should 
leave the ward within two hours after the delivery;
e) persons in quarantine or in isolation may not participate 
in the delivery nor enter the hospital premises.
The final decision regarding family assisted births de-
pends on the possibility of meeting the above-mentioned 
conditions and the decision of the head of the ward.
TRANSMISSION Of SARS-COV-2
SARS-CoV-2 is highly infective at 4°C which is decreas-
ing in the temperature of 25°C, although is still present 
at 33°C, and even at 38°C. Infectiousness depends on the 
environmental temperature and humidity and can even 
last for 3-5 days. SARS-CoV-2 is very stable in the urine as 
well as stool and can be contagious for 96 and 72 hours 
respectively [15]. This indicates existing risks for fecal-oral 
infection route as well as potential risk for infection via 
fresh water [16].
SARS-CoV-2 is very sensitive for wide array of disin-
fection products and chemical inactivators [2]. Bilal et al. 
[15] tested hospital rooms and bathrooms in 15 different 
locations occupied by COVID-19 patients revealing 87% 
and 60% positive samples, respectively. After routine 
cleansing and disinfection procedures all samples were 
negative.
Walsh et al performed systematic review based on 
113 publications from December 30, 2019 till May 12, 
2020. Analysis showed that viral load in the upper air-
way peaks at first days of clinical signs and remains high 
through first few days of infection. Viral shedding is not 
present after 14 days from the beginning of infection. Viral 
load in the stool reaches highest values later and remains 
present for longer time than in the upper airways. Viral 
load in the upper airway depends on the severity of the 
diseases and can be even 60 times higher in patients 
with severe course of the disease. Viral transmission 
may occur two days before the first symptoms appear 
and lasts for seven days of clinical symptoms, which was 
shown in the early publications. The authors stressed that 
presence of viral RNA in the upper airways is not proof 
of infectiousness, which depends directly on viral load. 
There is no correlation between viral load and patient’s 
age, which has been reported this same for children and 
adults [17].  
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ULTRASOUND ExAMINATION DURING 
COVID-19 PANDEMIC
Ultrasound diagnostics during ongoing pregnancy fol-
lowing the recommendations of the Ultrasound Section 
of the Polish Society of Gynecologists and Obstetricians 
must meet special requirements to minimize the risk of 
SARS-CoV-2 transmission. Naturally, the recommendations 
include triage — pre-selection of patients allowing ultra-
sound examinations only for asymptomatic patients with 
a negative history and when possible having recently made 
a negative SARS-CoV-2 test as a best option. 
During COVID-19 infection in pregnancy, ultrasound 
examination of fetal growth, amniotic fluid and umbili-
cal artery blood flow should be performed when clinically 
necessary.
In outpatient clinic, according to the Polish guidelines 
only the first, second and third trimester scans should be 
performed. As a precaution the number of vaginal scans 
should be minimized, when possible it is recommended to 
perform cervical length measurement by transabdominal 
examination [18].  
NEONATAL CARE DURING COVID-19 
PANDEMIC 
COVID-19 pandemic forced health care providers to 
establish guidelines focused on care of the newborns born 
to mothers infected with SARS-CoV-2. In the beginning 
of the pandemic during its first wave, in March and April 
2019 there were a series of the initial guidelines on this topic 
issued by The World Health Organization, American Acad-
emy of Pediatrics, American College of Obstetricians and 
Gynecologists, and European Academy of Pediatrics which 
were based on very limited knowledge of SARS-CoV-2 effect 
on newborns’ health. There were very diverse approaches 
to neonatal care, from strict isolation of the newborn from 
mother with formula feeding to almost normal, unaffected 
care with skin-to-skin and rooming-in. 
During the first wave of COVID-19 until the second wave 
of the pandemic more information on neonatal effect of 
maternal COVID-19 diseases has been gathered. Zhu and 
colleagues retrospectively analyzed the clinical course 
of 10 newborn babies of mothers with COVID-19 symp-
toms. This analysis showed that none of the women had 
been treated with antivirals prior to delivery despite the 
presence of clinical symptoms in two patients. The remain-
ing pregnant women developed symptoms within a few 
days following delivery. Fetal life-threatening symptoms 
such as hypoxemia associated with respiratory failure oc-
curred in six pregnant women. The studied cohort was eight 
male newborns and two female newborns of which six 
were born prematurely. The most observed clinical signs of 
respiratory failure in neonates were to be shallow breath-
ing, fever and tachycardia. Disorders of the gastrointestinal 
tract such as reflux, regurgitation (spitting up), and bloody 
discharge from the stomach were observed in four new-
borns. Radiographic changes of the chest were observed 
in seven neonates: pneumonia (4), respiratory distress syn-
drome (2), pneumothorax (1) and none presented with 
SARS-CoV-2 in nasopharyngeal discharge. Two neonates, 
born at 34 weeks of gestation presented with very serious 
symptoms of respiratory failure, thrombocytopenia and 
liver failure. One of the newborns developed intravascular 
coagulation syndrome but despite the administration of 
plasma, platelets and red blood cells, the child died on the 
ninth day of life. Another severely ill newborn was treated 
with blood products, immunoglobulin, glucocorticosteroids 
and low molecular weight heparin and was cured on the 
15th day of life [19]. 
One of the largest retrospectively analyzed cohort of 
newborns from SARS-CoV-2 infected mothers is study by 
Dumitriu et al. [20], from New York City. There were 101 new-
borns included in the study. Only one newborn was positive 
for the presence of SARS-CoV-2 but was asymptomatic. Out 
of all of them, 18 were admitted to neonatal intensive care 
unit (NICU) with non-COVID-19 related pathology. New-
borns born to mothers with severe/critical COVID-19 (10%) 
were born one week earlier [37.9 (IQR) 37.1–38.4 vs 39.1 (IQR) 
38.3–40.2, p = 0.02] and required more often phototherapy 
(30% vs 7%). None of the newborns presented any pathol-
ogy in the follow-up. It is important to mention that direct 
breastfeeding after appropriate hygiene was encouraged 
in this study. Authors concluded that there was no clinical 
evidence of vertical transmission in 101 newborns of moth-
ers positive for or with suspected SARS-CoV-2 infection, 
despite most newborns being cared for in rooming-in and 
directly breastfed. 
Salvatore et al., analyzed cohort of pregnant women 
who were tested for COVID-19. Out of 1481 deliveries 
positive were eight percent, which accounted for 120 neo-
nates. None of them were positive for SARS-CoV-2 on the 
first day of life, 83% were roomed in with mothers, and all 
were breastfed. Eight-two newborns had repeat PCR test at 
days 5–7 of life and all of them were also negative. Authors 
concluded that perinatal transmission of COVID-19 does 
not occur with optimal hygiene regime and rooming in 
with mothers is not increasing the risk for COVID-19 [21].
On the other hand, a less liberal approach for neona-
tal care is proposed by authors of the study by Farghaly 
et al. [22], in which their analysis showed significant as-
sociation between symptoms and SARS-CoV-2 status 
regarding skin-to-skin contact (p < 0.001). Both studied 
groups showed significant differences regarding isolation 
patterns (p < 0.001). There was only one newborn with 
positive results for SARS-CoV-2 admitted to the neonatal 
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intensive care unit (NICU). It has been shown that newborns 
of SARS-CoV-2 positive mothers were three times as likely to 
have desaturations, four times more likely to have poor feed-
ing and ten times more likely to be symptomatic at the 2nd 
week follow-up in comparison to newborns from negative 
mothers. This group concluded that neonates born to moth-
ers with confirmed or suspected SARS-CoV-2 are most of the 
time asymptomatic. Nevertheless there is still possibility for 
COVID-19 infection among newborns, thus in some cases 
isolation precautions should be considered and studied. In 
addition, testing these newborns by nasopharyngeal swab 
at least at 24 hours after birth and monitoring them for the 
development of symptoms for 14 days after birth is needed. 
So, one of the most important question from the neo-
natologist point of view is: What is the risk for intrauterine 
vertical COVID-19 infection? Recently, Kotlyar AK et al. [23], 
published results of quantitative analysis and revealed that 
out of 936 neonates from COVID-19 mothers, 27 neonates 
had SARS-CoV-2 viral RNA positive nasopharyngeal swab, 
indicating a pooled proportion of 3.2% for vertical transmis-
sion. SARS-CoV-2 viral RNA testing in neonatal cord blood 
was positive in 2.9% of samples, 7.7% of placenta samples, 
0% samples of amniotic fluid and urine samples and 9.7% of 
fecal swabs. Neonatal serology was positive in 3.7% (based 
upon the presence of IgM). Although these results suggest 
possibility for vertical SARS-CoV-2 transmission more stud-
ies are needed to clinically proof for this route of infection. 
Based on published retrospective analysis, observa-
tional studies and guidelines up to date of December 30th, 
2020 the following procedures for neonatal care during the 
COVID-19 pandemic should be followed: 
1. There is currently no clear evidence of intrauterine fetal 
infection with SARS-CoV-2. Although there is presence 
of viral genetic material in amniotic fluid, placenta and 
umbilical cord.
2. Every newborn baby of a COVID-19 positive mother 
should be tested for SARS-CoV-2 as soon as possible – to 
prevent contamination occurring after birth. Standard 
method is rt-PCR. Antigen test can be used to proof for 
end of viremia after infection,
3. After birth of a newborn from an infected COV-
ID-19 mother, the newborn does not need to be isolated 
from mother and can be cared in “rooming-in”. Mother 
and child should be hospitalized in special units dedi-
cated to COVID-19 patients in separate rooms in order to 
avoid cross-infections with other women. There should 
be dedicated personnel appointed to care. 
4. A newborn baby of a COVID-19 mother should be 
breastfed if mother’s clinical status is stable or may re-
ceive mother’s milk if the milk is pumped in accordance 
with all basic hygiene regulations. Up to date there is no 
evidence that mothers milk contains replicable RNA of 
SARS-CoV-2, contrary to the evidence for IgM antibody 
presence [24]. 
5. Newborns of mothers infected with SARS-CoV-2 should 
undergo all mandatory vaccinations. Newborns who 
have tested positive for SARS-CoV-2 and who have no 
clinical symptoms should receive vaccination for viral 
hepatitis B and tuberculosis preferably with consultation 
of a vaccinologist.
6. Lack of causal treatment for COVID-19 infection in new-
borns.
7. Discharge home as soon as possible, newborn should 
be picked by family member who is negative and not 
under quarantine.
8. Neonatal resuscitation:
a) should be performed in designated room by 
trained personnel secured with protective cloth-
ing, N95 masks, goggles, and gloves;
b) Resuscitation Equipment (based on NRP or ERC 
guidelines):
•	 infant radiant warmer, dry linen sheets, plastic 
bag,
•	 suction (pressure 80–100 mm Hg); preferred 
closed systems,
•	 T-piece resuscitator or nasal CPAP (settings: 
PEEP = 6 cm H2O, PIP = 20–25 cm H2O, FiO2 ac-
cording to gestational age, flow 6–10 L/min), 
masks with optimal size ranges, endotracheal 
tubes and laryngoscope of appropriate size, 
laryngeal mask if applicable, , self-inflating bag,
•	 other equipment: Videolaryngoscope if avail-
able and used at site, drugs according to local 
list, stethoscope, pulse ox, ECG electrodes.
c) transport incubator equipped with ventilator for 
neonatal transfer, 
d) d. delayed cord according to regular local guidelines.
9. Skin-to-skin contact possible based on the clinical and 
organizational conditions [25].
VACCINATION
At the end of December, the vaccinations against COV-
ID-19 were initiated in Poland. There were various doubts 
and questions raised regarding the safety of the new mRNA 
vaccine. During perinatal care there are two major issues 
related to vaccination that may need further explanations:
1. Vaccinations of the pregnant women
Since manufacturers of the vaccines did not include 
pregnant women in the phase III clinical trials, there 
is insufficient evidence to recommend routine use of 
COVID-19 vaccines during pregnancy. Joint Committee 
on Vaccination and Immunization (JCVI) advises that, 
for women who are offered vaccination, vaccination in 
pregnancy should be considered only where the risk of 
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development of Acute Respiratory Distress Syndrome 
(ARDS) is very high, or where the woman has underly-
ing conditions that put them at very high risk of serious 
complications of COVID-19. In these circumstances, clini-
cians should discuss the risks and benefits of vaccination 
with the woman, who should be told about the absence 
of safety data for the vaccine during pregnancy [26, 27].
2. Vaccinations of the breastfeeding women   
Due to outweighed benefits of breastfeeding as well 
as lack of evidence of associated risks to non-live vac-
cines during breastfeeding, JCVI allow for vaccination 
against COVID-19 of breastfeeding women.. Neverthe-
less, absence of safety data for the vaccination proce-
dure among breastfeeding women should be explained 
by medical personnel. 
JCVI does not advise routine pregnancy testing before 
receipt of a COVID-19 vaccine. Those who are trying to 
become pregnant do not need to avoid pregnancy after 
vaccination. These recommendations are in sync with rec-
ommendations by The Royal College of Obstetricians and 
Gynecologists
In summary: Women should discuss the benefits and 
risks of having the vaccine with their healthcare professional 
and commonly seek decision [26, 27].
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